B+
Bull case
20%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
OKUR
OnKure TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The company has substantial reported runway into 2029 and two named next-generation PI3Kα programs moving toward planned H1 2027 IND submissions. Successful execution could improve platform credibility and expand optionality [#SEC-8K-2026-08-04].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +0.6.
What can break
Both lead programs are preclinical/IND-enabling and depend on successful regulatory submission and clinical translation.
Momentum
43
Value
59
Sentiment
74
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.50 · Bull $6.50 · Bear $1.80Analysis 2026-09-01; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $15.50
Why
Momentum43 · Δ7d -10.4
Value59 · Δ7d 0.0
Sentiment74 · Δ7d +0.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +0.6.
Contradictions & invalidation
- • Both lead programs are preclinical/IND-enabling and depend on successful regulatory submission and clinical translation.
- • No direct, indication-matched peer set is supported by the packet, limiting valuation and read-through confidence.
- • The programs remain in IND-enabling work, with no clinical efficacy readout, consensus surprise, analyst revision, or target-change evidence in the packet.
Catalyst clock
2026-11-30
H1 2027 IND submissions for OKI-355 and OKI-345
Lead driver: Sentiment · See AI snapshot
Momentum
43
9% active weight
Current posture
7d trendSoftening
Δ7d
-10.4
Δ21d
-16.5
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.4
Sentiment
74
62% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+4.5
Why this grade
Composite grade B. Momentum 42.9 / Value 58.5 / Sentiment 74.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-01. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$166.44M
Beta
0.47
Shares Out
40.5M
P/E (TTM) · Derived
-0.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.39
Rev YoY
-
EPS YoY
-73.0%
Gross Margin
-
Op Margin
-
Net Debt
-$58.5M
Current Ratio
26.75
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data